Skip to main content
AdvisorShares Psychedelics ETF—— (—)Compass Pathways—— (—)Definium Therapeutics—— (—)GH Research—— (—)Helus Pharma—— (—)MIRA Pharmaceuticals—— (—)Neuphoria Therapeutics—— (—)Eli Lilly—— (—)Johnson & Johnson—— (—)AbbVie—— (—)Otsuka Pharmaceutical—— (—)Numinus Wellness—— (—)Optimi Health—— (—)PharmAla Biotech—— (—)Enveric Biosciences—— (—)Incannex Healthcare—— (—)Aurora Cannabis—— (—)Cronos Group—— (—)SNDL—— (—)Bright Minds Biosciences—— (—)PharmaTher Holdings—— (—)IM Cannabis—— (—)MariMed—— (—)Vireo Growth—— (—)
Loading prices
Back to the NewsWire

Pharmaphorum

Published November 16, 2026 · Updated November 17, 2026

Helus shares slide on psychedelic readout in depression - pharmaphorum

Read the full story at Pharmaphorum

The efficacy result looks strong, with the psychedelic achieving "statistically significant and clinically meaningful" 7.6-point improvement in.

Surfaced by 3 Google Alerts

  • Psychedelics
  • Magic mushrooms
  • Psychedelics europe